Ocugen jumps as FDA lifts clinical hold on COVID vaccine trial application

Hanall Biopharma

18/02/2022 22:45

** Biopharma co's shares  OCGN.O  climb 23.4% to $4.27 in
extended trading
    ** OCGN says U.S. FDA has lifted its clinical hold on OCGN's
application seeking clearance to begin adult clinical trials of
COVID-19 vaccine candidate BBV152, also known as Covaxin outside
the United States  urn:newsml:reuters.com:*:nGNX1LqHYQ
    ** In November last year, FDA had issued the clinical hold
on OCGN's application after identifying certain deficiencies
 urn:newsml:reuters.com:*:nL4N2SH2ZC
    ** Covaxin was developed by OCGN's India-based partner
Bharat Biotech; OCGN is co-developing it for the U.S. and
Canadian markets
    ** The vaccine has been approved for emergency use by the
World Health Organization and is currently under review by the
FDA for emergency use authorization for children between 2 and
18 years
    ** Up to Friday's close, OCGN stock had fallen by about
two-thirds over the past 12 months

 (Reporting by Ruhi Soni in Bengaluru;)
 ((Ruhi.Soni@thomsonreuters.com;
Twitter: https://twitter.com/ruhithere;))